Bruno John G, Richarte Alicia M, Phillips Taylor
Operational Technologies Corporation, 4100 NW Loop 410, Suite 230, San Antonio, TX 78229.
Microchem J. 2014 Jul 1;115:32-38. doi: 10.1016/j.microc.2014.02.003.
Fifty-two candidate DNA aptamer sequences were selected for binding to the cardiovascular biomarker B-type or brain natriuretic peptide (BNP). Candidate aptamers were screened to rank their relative affinities against BNP by an aptamer-based ELISA-like aptamer microplate assay (ELASA). The highest affinity aptamers from ELASA screening were also paired in all possible combinations and screened for electrochemiluminescence (ECL) assay potential in capture aptamer-magnetic bead and ruthenium trisbipyridine (Ru(bpy))-reporter aptamer sandwich formats. The top ECL sandwich combinations utilized the same aptamer pair in either capture or reporting roles with nanogram to low picogram per mL levels of detection even in 50% human serum. ECL assay sensitivity and linearity even in 50% human serum suggest that the aptamer-based assay is at least comparable to other reported immunoassays for BNP.
选择了52个候选DNA适配体序列用于与心血管生物标志物B型或脑钠肽(BNP)结合。通过基于适配体的酶联免疫吸附测定样适配体微孔板分析(ELASA)筛选候选适配体,以对它们与BNP的相对亲和力进行排名。来自ELASA筛选的具有最高亲和力的适配体也以所有可能的组合配对,并针对捕获适配体-磁珠和三联吡啶钌(Ru(bpy))-报告适配体夹心形式的电化学发光(ECL)分析潜力进行筛选。即使在50%人血清中,顶级ECL夹心组合在捕获或报告角色中使用相同的适配体对,检测水平可达每毫升纳克至低皮克。即使在50%人血清中,ECL分析的灵敏度和线性表明基于适配体的分析至少与其他报道的BNP免疫分析相当。